Literature DB >> 23509995

A bedside definition of acute respiratory distress syndrome based on a conceptual model.

Shigeki Kushimoto.   

Abstract

Entities:  

Mesh:

Year:  2013        PMID: 23509995      PMCID: PMC3672532          DOI: 10.1186/cc12539

Source DB:  PubMed          Journal:  Crit Care        ISSN: 1364-8535            Impact factor:   9.097


× No keyword cloud information.

We would like to thank Perel for his discerning comments [1], published in the previous issue of Critical Care, about our study [2]. We agree with his pathophysiology-based view of the diagnosis of acute respiratory distress syndrome (ARDS). In regard to his first concern, we excluded 14 patients, who were judged to have respiratory failure secondary to sepsis-induced increased pulmonary vascular permeability, because owing to hypovolemia their values of extravascular lung water indexed to predicted body weight (extravascular lung water index, or EVLWI) were less than 10 mL/kg. Because EVLWI in patients with ARDS correlated not only with pulmonary vascular permeability but also with cardiac preload [2], we interpreted that their low levels of EVLWI could be secondary to inappropriate preload. Although the mechanisms of hypoxemia were unclear, ventilation/perfusion mismatch may occur because of lung perfusion failure. The pathophysiology of the condition of these patients must be clarified in the future. In regard to the concern that the experts may have had some idea of the pulmonary vascular permeability index (PVPI) value during the exclusion and allocation processes, the value of EVLWI was provided only to determine whether the patients had pulmonary edema (EVLWI of at least 10 mL/kg), and the value itself was not discussed during the review process. Therefore, estimating the PVPI value must be impractical. We believe that the direct measurement of PVPI and EVLW will provide an important advance over current methods of assessing the presence and origin of lung edema and the precise condition of ARDS [3] and could be incorporated into the future definition of ARDS.

Authors' response

Azriel Perel I thank Kushimoto for addressing my commentary [1] on his group's study on the clinical usefulness of EVLWI and PVPI in defining ARDS [2]. Kushimoto points out that the reason for excluding 14 patients from the final analysis was that, although they were judged to have sepsis-induced increased pulmonary vascular permeability, they had normal EVLW values due to inappropriate preload (hypovolemia). Furthermore, he believes that the weak correlation between EVLWI and the indexed intrathoracic blood volume (ITBVI) supports this physiologic explanation. Fluid loading indeed may increase EVLW [4] whereas the institution of negative fluid balance therapy may decrease elevated EVLW values [5]. However, in the presence of sepsis-induced increased pulmonary vascular permeability, which is associated with severe hypoxemia (as, presumably, in the case of this excluded group of patients), pulmonary edema cannot be prevented or completely resolved by hypovolemia per se. The presence of such a theoretical extreme hypovolemia can also be ruled out in these patients because patients with a cardiac index of less than 1.5 L/minute per m2 were excluded from the study [2]. Furthermore, Figure 4 in the article by Kushimoto and colleagues [2] shows that ARDS patients with normal ITBVI values (850 to 1,000 mL/m2) may have very high EVLWI values. Indeed, the combination of hypovolemia and pulmonary edema is not rare and may present a challenging 'therapeutic conflict' [6]. I agree with Kushimoto that the pathophysiology of these patients needs further clarification.

Abbreviations

ARDS: acute respiratory distress syndrome; EVLW, extravascular lung water; EVLWI: indexed extravascular lung water; ITBVI: indexed intrathoracic blood volume; PVPI: pulmonary vascular permeability index.

Competing interests

SK declares that he has no competing interests. AP is a member of the Medical Advisory Board of Pulsion Medical Systems, Munich, Germany.
  6 in total

1.  Pulmonary edema in hypovolemic patients: how can we predict it in clinical practice?*.

Authors:  Mikhail Y Kirov
Journal:  Crit Care Med       Date:  2012-03       Impact factor: 7.598

2.  Improved outcome based on fluid management in critically ill patients requiring pulmonary artery catheterization.

Authors:  J P Mitchell; D Schuller; F S Calandrino; D P Schuster
Journal:  Am Rev Respir Dis       Date:  1992-05

3.  Predictors of pulmonary edema formation during fluid loading in the critically ill with presumed hypovolemia*.

Authors:  Jurjan Aman; A B Johan Groeneveld; Geerten P van Nieuw Amerongen
Journal:  Crit Care Med       Date:  2012-03       Impact factor: 7.598

4.  Acute respiratory distress syndrome: the Berlin Definition.

Authors:  V Marco Ranieri; Gordon D Rubenfeld; B Taylor Thompson; Niall D Ferguson; Ellen Caldwell; Eddy Fan; Luigi Camporota; Arthur S Slutsky
Journal:  JAMA       Date:  2012-06-20       Impact factor: 56.272

5.  The clinical usefulness of extravascular lung water and pulmonary vascular permeability index to diagnose and characterize pulmonary edema: a prospective multicenter study on the quantitative differential diagnostic definition for acute lung injury/acute respiratory distress syndrome.

Authors:  Shigeki Kushimoto; Yasuhiko Taira; Yasuhide Kitazawa; Kazuo Okuchi; Teruo Sakamoto; Hiroyasu Ishikura; Tomoyuki Endo; Satoshi Yamanouchi; Takashi Tagami; Junko Yamaguchi; Kazuhide Yoshikawa; Manabu Sugita; Yoichi Kase; Takashi Kanemura; Hiroyuki Takahashi; Yuichi Kuroki; Hiroo Izumino; Hiroshi Rinka; Ryutarou Seo; Makoto Takatori; Tadashi Kaneko; Toshiaki Nakamura; Takayuki Irahara; Nobuyuki Saito; Akihiro Watanabe
Journal:  Crit Care       Date:  2012-12-11       Impact factor: 9.097

6.  Extravascular lung water and the pulmonary vascular permeability index may improve the definition of ARDS.

Authors:  Azriel Perel
Journal:  Crit Care       Date:  2013-01-24       Impact factor: 9.097

  6 in total
  1 in total

1.  The INVENT COVID trial: a structured protocol for a randomized controlled trial investigating the efficacy and safety of intravenous imatinib mesylate (Impentri®) in subjects with acute respiratory distress syndrome induced by COVID-19.

Authors:  Leila Atmowihardjo; Job R Schippers; Imke H Bartelink; Pierre M Bet; Nienke van Rein; Keith Purdy; David Cavalla; Valérie Comberiati; Andrew McElroy; Sue D Snape; Harm Jan Bogaard; Leo Heunks; Nicole Juffermans; Marcus Schultz; Pieter R Tuinman; Lieuwe D J Bos; Jurjan Aman
Journal:  Trials       Date:  2022-02-16       Impact factor: 2.279

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.